NO20045527L - Kombinasjon av en IBAT-inhibitor og et metallsalt for behandling av diare - Google Patents

Kombinasjon av en IBAT-inhibitor og et metallsalt for behandling av diare

Info

Publication number
NO20045527L
NO20045527L NO20045527A NO20045527A NO20045527L NO 20045527 L NO20045527 L NO 20045527L NO 20045527 A NO20045527 A NO 20045527A NO 20045527 A NO20045527 A NO 20045527A NO 20045527 L NO20045527 L NO 20045527L
Authority
NO
Norway
Prior art keywords
combination
metal salt
diarrhea
treatment
ibat inhibitor
Prior art date
Application number
NO20045527A
Other languages
English (en)
Inventor
Eva-Karin Anderberg
Erik Soderlind
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20045527L publication Critical patent/NO20045527L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

2005-04-07 Sammendrag Kombinasjon omfattende en IBAT-inhibitor eller et farmasøytisk akseptabelt salt, solvat, solvat av et slikt salt eller et prodrug derav og et metallsalt, hvor metallsaltet blir formulert for å frigjøres i terminal ileum, caecum og/eller kolon, er beskrevet. Preparater inneholdende denne kombinasjon og anvendelser av kombinasjonen er også besktevet.
NO20045527A 2002-07-13 2004-12-17 Kombinasjon av en IBAT-inhibitor og et metallsalt for behandling av diare NO20045527L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0216321.0A GB0216321D0 (en) 2002-07-13 2002-07-13 Therapeutic treatment
PCT/GB2003/002978 WO2004006899A1 (en) 2002-07-13 2003-07-09 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea

Publications (1)

Publication Number Publication Date
NO20045527L true NO20045527L (no) 2005-04-07

Family

ID=9940407

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045527A NO20045527L (no) 2002-07-13 2004-12-17 Kombinasjon av en IBAT-inhibitor og et metallsalt for behandling av diare

Country Status (20)

Country Link
US (1) US20060083790A1 (no)
EP (1) EP1539120A1 (no)
JP (1) JP2005536502A (no)
KR (1) KR20050027108A (no)
CN (1) CN1668286A (no)
AR (1) AR040553A1 (no)
AU (1) AU2003246932A1 (no)
BR (1) BR0312427A (no)
CA (1) CA2492374A1 (no)
GB (1) GB0216321D0 (no)
IL (1) IL166068A0 (no)
IS (1) IS7678A (no)
MX (1) MXPA05000461A (no)
NO (1) NO20045527L (no)
PL (1) PL374665A1 (no)
RU (1) RU2004138083A (no)
TW (1) TW200418821A (no)
UY (1) UY27890A1 (no)
WO (1) WO2004006899A1 (no)
ZA (1) ZA200500212B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
ATE349214T1 (de) 2001-09-08 2007-01-15 Astrazeneca Ab Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
PL2125711T3 (pl) 2007-03-08 2014-05-30 Albireo Ab Pochodne kwasy 3-fenylopropionowego oraz ich zastosowanie w leczeniu nieswoistego zapalenia jelit
KR101890959B1 (ko) * 2010-11-08 2018-08-22 알비레오 에이비 간질환 치료를 위한 ｉｂａｔ 억제제
BR112013010705B1 (pt) 2010-11-08 2020-11-17 Albireo Ab uso de um inibidor de ibat e um coagulante de ácido biliar, e formulação farmacêutica
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
KR101674806B1 (ko) * 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
KR101844184B1 (ko) * 2017-07-21 2018-04-02 씨제이헬스케어 주식회사 아미노알킬벤조티아제핀 유도체의 용도
CA3071285A1 (en) * 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3100113A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JOP20200297A1 (ar) 2018-06-20 2020-11-22 Albireo Ab تعديلات بلورية للأوديفيكسيبات
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
WO2020161216A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
PL3921028T3 (pl) 2019-02-06 2023-02-13 Albireo Ab Związki benzotiadiazepinowe i ich zastosowanie jako modulatory kwasów żółciowych
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
TW202134220A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
EP4069247A1 (en) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
DK4069360T3 (da) 2019-12-04 2024-02-26 Albireo Ab Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023203248A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2024121434A1 (en) 2022-12-09 2024-06-13 Albireo Ab Asbt inhibitors in the treatment of renal diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
SE9901387D0 (sv) * 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6287609B1 (en) * 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
SE0003766D0 (sv) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation

Also Published As

Publication number Publication date
AR040553A1 (es) 2005-04-13
UY27890A1 (es) 2004-02-27
EP1539120A1 (en) 2005-06-15
GB0216321D0 (en) 2002-08-21
US20060083790A1 (en) 2006-04-20
IS7678A (is) 2005-01-28
BR0312427A (pt) 2005-04-19
ZA200500212B (en) 2006-07-26
KR20050027108A (ko) 2005-03-17
IL166068A0 (en) 2006-01-15
WO2004006899A1 (en) 2004-01-22
CN1668286A (zh) 2005-09-14
PL374665A1 (en) 2005-10-31
RU2004138083A (ru) 2005-10-10
MXPA05000461A (es) 2005-03-23
TW200418821A (en) 2004-10-01
JP2005536502A (ja) 2005-12-02
AU2003246932A1 (en) 2004-02-02
CA2492374A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
NO20045527L (no) Kombinasjon av en IBAT-inhibitor og et metallsalt for behandling av diare
UA84141C2 (ru) Применение ингибитора пктжк для лечения или профилактики запора
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
AP2001002224A0 (en) Benzoheterocycles and their use as MEK inhibitors.
MXPA03006929A (es) Composiciones que forman pelicula poliacrilica.
GB9929552D0 (en) Compounds
LU91680I2 (fr) "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)"
IL148313A0 (en) N-heterocyclic derivatives as nos inhibitors
IL166432A0 (en) Composition containing an androgenous 11?-halogen steroid and a progestational hormone and male contraceptive based on said composition
GEP20084539B (en) 4-tetrazolyl-4phenylpiperidine derivatives for treating pain
MXPA06001273A (es) Compuestos novedosos.
IL165155A0 (en) Process for the manufacture of quinoline derivatives
GB0114185D0 (en) Compounds
HUP0203304A2 (hu) Prosztatarák megelőzésére szolgáló kemoterápiás módszer és készítmény
TW505733B (en) Electronic circuits for plasma generating devices
MXPA04004263A (es) Hidrazono-malonitrilos.
EP1140900A4 (en) PYRAZOLE COMPOUNDS AND USE OF SUCH COMPOUNDS
IL155263A0 (en) Pharmaceutical solutions of modafinil compounds
MY121046A (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
DE60002570D1 (de) Schluckbare tabletten mit einem hohen gehalt an n-acetylcystein
DE60127131D1 (de) Tricyclische imidazopyridine
NZ330244A (en) Isoxazole derivatives useful in the treatment of inflammatory diseases
GB9923710D0 (en) Chemical compounds
WO2005018562A3 (en) Blockade of mtor to prevent a hormonal adaptive response
ATE282608T1 (de) Chinoxalindionen